-+ 0.00%
-+ 0.00%
-+ 0.00%

BioRestorative Secures Notice of Allowance For Japanese Patent For ThermoStem Platform

Benzinga·10/27/2025 11:32:55
Listen to the news

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major intellectual property milestone: the Japanese Patent Office has issued a Notice of Allowance for the Company's ThermoStem® platform.

The newly allowed patent provides broad protection for BioRestorative's allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) technology, designed to treat obesity and metabolic disorders. These claims are materially stronger than previously granted patents, covering not only the therapeutic cells themselves, but also multiple methods of encapsulation and delivery — including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolding systems.

With this allowance, BRTX is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, one of the fastest-growing therapeutic categories in the world.